Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study

Circulation

Volumn 94, Issue 3, 1996, Pages 273-278

  Lamarche, Benoît ^a   Moorjani, Sital ^a   Lupien, Paul J ^a   Cantin, Bernard ^a   Bernard, Paul Marie ^a   Dagenais, Gilles R ^b   Després, Jean Pierre ^a,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

apolipoproteins; heart diseases; ischemia; lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD LEVEL; CANADA; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART INFARCTION; HUMAN; IMMUNOELECTROPHORESIS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029832009     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.3.273     Document Type: Article

References (46)

1. Kannel WB, Neaton JD, Wenworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Am Heart J. 1986;112:825-836.
2. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
3. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986;74:1217-1225.
4. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
5. Gordon DJ, Rifkind BM. High density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
6. Manninen V, Tenkanen L, Koshinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
7. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
8. Avogaro P, Bittolo Bon G, Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipid for atherosclerosis? Lancet. 1979;1:910-913.
9. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO Jr. Association of coronary atherosclerosis with hyperapobetali-poproteinemia [increased protein but normal cholesterol levels in human low density (β) lipoproteins]. Proc Natl Acad Sci USA. 1980;77:604-608.
10. Brunzell HD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. Apoprotein B and AI and coronary heart disease in humans. Arteriosclerosis. 1984;4:79-83.
11. Bhatnagar D, Durrington PN. Clinical value of apolipoprotein measurements. Ann Clin Biochem. 1991;28:427-437.
12. Genest JJ, Bard JM, Fruchart JC, Ordovas JM, Wilson PFW, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary heart disease. Atherosclerosis. 1991;90:149-157.
13. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988;1:1070-1073.
14. Genest JJ, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormality in men with premature coronary heart disease. J Am Coll Cardiol. 1992;19:792-802.
15. Sedlis SP, Shechtman KB, Ludbrook PA, Sobel BE, Schonfeld G. Plasma apoproteins and the severity of coronary artery disease. Circulation. 1986;73:978-986.
16. Kwiterovich PO Jr, Coresh J, Smith H, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and AI, and other risk factors in men and women with premature coronary heart disease. Am J Cardiol 1992;69:1015-1021.
17. Salonen JT, Salonen R, Penttilä I, Herranen J, Jauhiainen M, Kantola M, Lappeteläinen R, Mäenpää PH, Alfthan G, Puska P. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol. 1985;56:226-231.
18. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Hadow JE. Apolipoproteins and ischemic heart disease: implications for screening. Lancet. 1994;343:75-79.
19. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.
20. Sniderman AD, Genest J Jr. The measurement of apolipoprotein B should replace the conventional lipid profile in screening for cardiovascular risk. Can J Cardiol. 1992;8:133-140.
21. Vega GL, Grundy SM. Does measurement of apolipoprotein have a place in cholesterol management? Arterioscler Thromb. 1990;10: 668-671.
22. Sniderman AD. Apolipoprotein B and apolipoprotein AI as predictors of coronary heart disease. Can J Cardiol. 1988;4:24A-30A.
23. Dagenais GR, Robitaille NM, Lupien PJ, Christen A, Gingras S, Moorjani S, Meyer F, Rochon J. First coronary heart disease event rates in relation to major risk factors: Québec Cardiovascular Study. Can J Cardiol. 1990;6:274-280.
24. Lamarche B, Després JP, Moorjani M, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol. 1995;75:1189-1195.
25. Cantin B, Moorjani S, Dagenais GR, Lupien PJ, Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Québec Cardiovascular Study). Am J Cardiol. 1995;75:1224-1228.
26. Marmot MG, Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. Alcohol and coronary heart disease. Int J Epidemiol. 1984;13:160-167.
27. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 1984;108:150-158.
28. Moorjani S, Dupont A, Labrie F, Lupien PJ, Brun LD, Gagné C, Giguère M, Bélanger A. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 1987;36:244-250.
29. 2 precipitation procedures for estimating cholesterol in high-density lipoproteins. Clin Chem. 1978;24:323-338.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
31. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1960;5:609-610.
32. Rifkind BM, Segal P. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. JAMA. 1983;250:1869-1872.
33. Castelli C, Cooper GR, Doyle JT. Distribution of triglyceride and total LDL-C and HDL-C in several populations: a cooperative lipoprotein phenotyping study. J Chronic Dis. 1977;30:147-154.
34. Luria MH, Jacob JE, Sapoznikov D, Gotsman MS. Cardiovascular risk factor clustering and ratio of total cholesterol to high-density lipoprotein cholesterol in angiographically documented coronary artery disease. Am J Cardiol. 1991;67:31-36.
35. Young SG. Recent progress in understanding apolipoprotein B. Circulation. 1990;82:1574-1594.
36. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
37. Kesäniemi YA, Beltz WF, Grundy SM. Comparisons of metabolism of apolipoprotem B in normal subjects, obese patients, and patients with coronary heart disease. J Clin Invest. 1985;76:586-595.
38. Kesäniemi YA, Grundy SM. Overproduction of low-density lipoproteins associated with coronary heart disease. Arteriosclerosis. 1983;3:40-46.
39. Kwiterovich PO, Sniderman AD. Atherosclerosis and apoproteins B and A-I. Prevent Med. 1983;12:815-834.
40. O'Brien T, Nguyen TT, Hallaway BJ, Hodge D, Bailey K, Holmes D, Kottke BA. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:228-231.
41. Maciejko JJ, Holmes DR, Kottke BA, Zinstmeister AR, Dihn DM, Mao SJT. Apolipoprotein A-I as a marker of angiographically assessed coronary artery disease. N Engl J Med. 1983;309:385-389.
42. Ishakawa T, Fidge N, Thelle DS, Forde OH, Miller NE. The Thromso heart study: serum apolipoprotein A-I concentration in relation to future coronary heart disease. Eur J Clin Invest. 1978;8:179-182.
43. Rader DJ, Hoeg JM, Brewer HB. Quantitaten of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-1025.
44. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
45. Marcovina SM, Albers JJ, Kennedy H, Mai JV, Henderson LO, Hannon WH. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-1 and B, IV: comparability of apolipoprotein B values by use of international reference material. Clin Chem. 1994;40:586-592.
46. Green MS, Heiss G, Rifkind BM, Cooper GR, Williams OD, Tyroler HA. The ratio of plasma high-density lipoprotein cholesterol to total and low-density lipoprotein cholesterol: age-related changes and race and sex differences in selected North American populations. Circulation. 1985;72:93-104.